Lakeland finishes sampling, mapping program at Star
LAKELAND RESOURCES INC. PROVIDES UPDATE ON 2014 EXPLORATION
Lakeland Resources Inc. is providing an update on recent and planned work at its 100-per-cent-owned Athabasca basin uranium properties.
Highlights
- Star uranium property: completion of follow-up mapping and prospecting at the Star uranium property. This work was completed in order to define the deposit model and the source of the gold, Platinum group element (PGE) and rare earth element (REE) mineralization observed during the fall of 2013;
- Lazy Edward Bay property: exploration permits have been received for the proposed summer work program and crews will begin mobilization to the property as soon as possible. The BAY trend will be the focus of exploration;
- Fond Du Lac property: exploration permits have been received for the proposed summer work program and crews will begin mobilization to the property as soon as possible. The Fond du Lac property is targeting a coincident geochemical and conductive target at the margin of the Athabasca basin.
Star uranium property
Crews from Dahrouge Geological Consulting Ltd. recently completed a six-day sampling and mapping campaign at the Star uranium property. A total of 73 rock samples and 124 soil samples were collected from in and around the uplifted basement block at the northeastern portion of the property, immediately north of the margin of the Athabasca basin. This work was completed in order to define the deposit model and the source of the gold, platinum group element and rare earth element results obtained in the fall of 2013. The 2013 sampling explored a small portion of the uplifted basement outcrop on the Star property. Anomalous concentrations of gold (up to 5.7 grams per tonne gold), platinum group elements (0.75 g/t PGE), rare earth elements (up to 6.9 per cent total rare earth oxides (TREO)) and highly anomalous uranium suggest the presence of a robust hydrothermal system.
Lazy Edward Bay property
Exploration permits have been received for the proposed summer work program, and mobilization to the property will begin as soon as possible. The BAY trend will be tested with a RadonEX survey. This and other targets will be prospected in order to locate boulders or other surface expressions of shallow unconformity-style uranium mineralization.
The BAY trend consists of two parallel conductive trends at the southern margin of the Athabasca basin. The BAY trend is highlighted by historic exploration of Uranerz in 1982, where drill hole LE-50 intersected the basement rocks about one kilometre south of the Athabasca sandstones. Moderately chloritized, sericitized and weakly hematized migmatitic, graphitic pelite returned an assay value of 770 parts per million uranium along with anomalous boron, nickel, pathfinder metals (Sask AR: 74G07-0042).
Fond Du Lac property
Exploration permits have been received for the proposed summer work program, and crews will begin mobilization to the property as soon as possible. The Fond du Lac property is targeting a coincident geochemical and conductive target at the margin of the Athabasca basin.
National Instrument 43-101 disclosure
The technical information above has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 and reviewed on behalf of the company by Neil McCallum, PGeo, of Dahrouge Geological Consulting Ltd., a qualified person.
- Published in Mining
Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
VANCOUVER, BC–(Marketwired – August 12, 2014) – Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the “Company”) announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization’s anti-aging project.
The loan, co-funded by Bpifrance and the district of Haute Normandie, will be dispersed in lump sums and is strictly allocated for advancement of the anti-aging compounds into preclinical testing. Repayment of the loan will be made in installments, beginning in Q3 2018 with the majority being paid after 2020. The company expects to be into substantial milestone and royalty payments before any repayment of the loan begins.
“With the tremendous support provided by this loan the need to arrange financings over the next 12 to 18 months are anticipated to be minimal,” reports CEO and Chairman of Sirona Biochem, Dr. Howard Verrico. “The funding received from Bpifrance and the district of Haute Normandie will enable us to start testing our library of anti-aging compounds without dilution. We are very excited about the potential of these compounds and the interest shown in them.”
The global anti-aging product market is currently valued at over $220 Billion USD with a CAGR of 5.2{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}. It’s expected to be nearly $285 Billion USD by the year 2018.1
About Sirona Biochem and TFChem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com or www.tfchemistry.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Life Sciences
Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors’ Video
VANCOUVER, BC, Aug 21, 2014 (Marketwired via COMTEX) — Sirona Biochem Corp. (SBM) (frankfurt:ZSB) launches global awareness campaign with ambassadors’ video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project.
“The time and effort put into this video illustrates just how dedicated the Cousteaus are to the relationship with Sirona Biochem,” said Howard Verrico, founder and CEO. “Having Jean-Michel and Fabien’s support for this project serves as a reminder of the immense potential value in these compounds.”
Jean-Michel Cousteau and Fabien Cousteau (son and grandson of Jacques Cousteau) are brand ambassadors for Sirona’s glycoprotein project. The project has also been generously supported by Bpifrance (the French Public Investment Bank) and the district of Haute Normandie with funding of CDN$1.2 million in the form of a no-interest loan.
The video can be viewed at the following link: http://youtu.be/s0PDhFOl6Ck
(with German subtitles: http://youtu.be/j5LDgIyzC3Y)
Sirona Biochem also announces attendance at the upcoming BIO Europe conference in Frankfurt Germany Nov 3-5 2014 with support from BIOTECanada and the Canadian Trade Commissioner Service, Global Opportunities for Associations (GOA) program.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Life Sciences
Soros Doubles YPF Stake in Argentina’s Nascent Shale Boom
George Soros’s $28 billion family office more than doubled its stake in YPF SA, making the state-controlled oil producer its biggest U.S.-traded stock holding two years after Argentina seized control of the company.
Soros Fund Management LLC added 8.47 million shares of YPF in the second quarter, according to a filing yesterday, bringing its position to 3.5 percent of the American depositary receipts. That was worth $450 million at the end of June, making Soros the fourth-biggest holder. The stock rallied today. click here to read the full article – http://www.bloomberg.com/news/2014-08-14/soros-adds-to-ypf-trims-teva-exits-monster-in-quarter.html
- Published in Blog
How job recruiters screen you on LinkedIn
There are 277 million users on LinkedIn, according to the company’s latest results, and many of them — though not all — are probably competing for the same jobs. To improve your chances of scoring the next great gig, it helps to know how recruiters use the site.
Recruiters scour the world’s most popular professional networking site looking for the perfect candidate, but there’s a lot they do before they even get to your profile page. Some 93{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of hiring managers search LinkedIn LNKD, -0.36{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} for recruits, according to a 2013 survey by career website Jobvite; 65{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} search Facebook FB, +1.24{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and 55{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} consult Twitter TWTR, +0.85{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} accounts. Another 18{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of recruiters search Google+ GOOG, +1.45{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and, in case there are any homemade videos lurking about, 15{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} will type your name into YouTube. Rule No. 1: “Your LinkedIn profile should be public,” says Jenny Foss, president of the Ladder Recruiting Group in Portland, Ore.
U.S. adds 288,000 jobs as winter lull fades
Americans gained jobs at the fastest pace in more than two years last month and the jobless rate plunged to 6.3{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}, a sign the economy has rebounded from a winter rut.
Most people spend so much time crafting their pitch, they forget about how they appear in a search result. “It’s the first thing that recruiters look at,” says Nicole Greenberg Strecker, managing director of recruitment agency STA Worldwide in Chicago, Ill. Your bio should include title, industry and location. “If you want to work in Silicon Valley and live in Kansas, change your location to Silicon Valley on LinkedIn. Recruiters search zip codes.” And the title should be razor-sharp. “Don’t write senior analyst at Ernst & Young, write hedge fund financial analyst at Ernst & Young,” says Jeremy Roberts, editor of Sourcecon, a blog and conference series for recruiters.
Recruiters punch in keywords, not buzzwords. When fine-tuning their initial search to find high-performing candidates, for instance, they’ll look for terms like “won,” “sold,” “achieved,” “built” and “president’s club.” No software is too old to mention. Technology recruitment consultants look for people who are proficient in WordPress because many companies don’t have the latest programs, Roberts says. And if you use in-demand open-sourced software like Ruby on Rails, say so. “It will save you a lot of spam,” he says; recruiters also recoil at buzzwords like “maven,” “guru,” “prophet” and “ninja” (unless you’re a black belt or a mutant turtle).
Leave a trail of virtual crumbs that lead to your profile. Hiring professionals lurk within LinkedIn industry groups and blogs, says Tamryn M. Hennessy, a vice president of career services at Rasmussen College. “Join them, especially if you want to change industries,” she says. “It’s a tremendous way to get smart about an industry and get on a recruiter’s radar.” Take part in the conversation, Hennessy adds, but only if you have something to say. Beware of criticism, says Piera Palazzolo, senior vice president for marketing at Dale Carnegie Training. “Never complain or express sour grapes,” she says. “It’s not Facebook (FB), it’s a professional network.”
Once they arrive on your page, you want to keep them there. “LinkedIn is speed dating for professionals,” says Grace Killelea founder and CEO of Half The Sky Women’s Leadership Institute. Recruiters are looking for reasons not to court you and anything that appears odd will be a red alert. “If there are gaps in your work history, fill that in, otherwise recruiters are going to get nervous,” she says. “Many people who were laid off are not comfortable filling in those gaps, but they absolutely need too.” Include details of volunteer work or, if it’s true, add “consulting,” she adds. Killelea’s golden rule for LinkedIn (and life): “If you can’t hide it, decorate it.”
Older job-seekers need to walk a fine line. Unless you made the cover of “Time” or discovered a solar galaxy, experience has a shelf life on LinkedIn, says Scott Dobroski, career trends analyst at Glassdoor. There’s no need to wax lyrical about a job that’s more than 10 years old, he says. And those who graduated from college a decade ago may want to exclude the date they graduated. “Your college graduation date will age you,” he says, “and although ageism is illegal, it’s happening all the time.” On the other hand, if you’re applying for a job as CEO of a Fortune 500 company and you graduated in 1986, it’s okay to leave the date, Dobroski says.
Most recruiters won’t care whether you have 1,000 endorsements, experts say. They’re regarded as the confetti of the digital world: Scattered too randomly and, as such, they lose meaning. Recruiters are actually looking for thoughtful recommendations from a well-respected peer or former employer, Palazzolo says. “I get endorsed for things that I don’t know how to do,” she says. “People want to see you’ve developed solid relationships.” That said, Foss says people should manage their skills and endorsements, rather than letting other people choose them, and an endorsement from a very big name could help.
Employers will also try to gauge your personality from your presentation. There’s a fine line between arrogance and confidence, Roberts says. Some tips: “Don’t put you’re a member of Mensa,” he says. “People have to seek out Mensa membership. Most hiring managers don’t want to hire someone who’s smarter than them.” But it’s smart to write, “increased conference attendance by 40{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce},” instead of a passive job description like, “conference manager.” People don’t want to read a LinkedIn profile that resembles a self-published memoir. “Don’t pompously refer to yourself in the third person,” Foss adds.
Recruiters assess photos differently, depending on the industry, says Killelea. Only include your dog if you’re a dog walker or dog groomer, she adds. Photos over two years old should be updated, she says. Selfies are a no-no, says Tim Sackett, president of HRU Technical Resources, an information technology and engineering staffing firm in Lansing, Mich. “Ask yourself, “If my grandmother looked at this picture, would she be proud?’” Sackett has seen LinkedIn photos of a woman dressed in an American flag and a man in blurry selfie taken in his bedroom.
- Published in Blog
Here are the most and least expensive states to live in the U.S.
(Updates with link to most and least expensive cities to live in the U.S.)
For the first time, the Commerce Department’s Bureau of Economic Analysis released price-adjusted estimates of personal income for states and metropolitan areas for 2008 to 2012, and it shows that, at the very least, it’s more expensive for Members of Congress to live in the nation’s capital on their $174,000 salary than in any state from which they hail.
The results show the District of Columbia, in 2012, had the highest “regional price parity” of any state. Granted, D.C.’s really a city, not a state, and set against their more natural comparisons, it ranks fifth, behind the Urban Honolulu area, New York-Newark-Jersey City, San Jose-Sunnyvale-Santa Clara, Bridgeport-Stamford-Norwalk and San Francisco-Oakland-Hayward. Beaches, hedge funds and technology are the key to prices, evidently.
The cheapest metro areas, by this methodology, were Danville, Ill.; Jefferson City, Mo.; Jackson, Tenn.; Jonesboro, Ark.; and Rome, Ga.
See related look at most and least expensive cities to live in the U.S.
Put another way,it costs 54{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} more to live in Honolulu than in Danville.
The top five states (outside of D.C.) were Hawaii, New York, New Jersey, California and Maryland, and the bottom five states were Mississippi, Arkansas, Alabama, Missouri and South Dakota. So, it costs 36{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} more to live in Hawaii than in Mississippi.
The BEA says it produced the report in large part so people and businesses can have a better understanding how their personal income may be impacted by a job change or move. There is regional consumer price index data, but those statistics aren’t designed for regional or city comparisons, whereas this data is, a spokesman says.
- Published in Blog
5 apps to improve your love life
Can an app improve your relationship?
Millions of people use dating apps, but many need help when they actually embark on a relationship. The good news: There are apps to help turn romance Luddites into Lotharios.
There are thousands of apps that may improve couples’ relationships and sex lives. For couples who need help with the latter, there are apps that could teach couples new tricks, says Rick Singer, CEO of GreatApps.com, a site that reviews apps. But Singer says it’s worth approaching the subject of bringing an app into the bedroom cautiously. “I’m not sure that someone’s significant other wants to hear, ‘I downloaded this app so we can enjoy a better sex life,’” he says.
“It’s the latest instance of sex driving technology,” says Patchen Barss, author of “The Erotic Engine,” about the evolution of sexuality and technology. We’ve come a long way since the Victorian era, when gentleman carried X-rated Stanhope microphotographs in their pocket watches, he says.
And when it comes to improving couples’ relationships outside the bedroom, sometimes apps that have nothing to do with love or sex can provide incidental help: Daniel Hamermesh, professor of economics at The University of Texas at Austin, who has been married for five decades, uses CityMaps2Go ($1.99), an offline map and travel guide, when traveling with his wife, as well as IMDB’s free app for movie trivia. “They’re not designed to help your marriage per se, but they’ve saved us a lot of time and argument.”
Reality shows are changing the way you watch TV—even if you aren’t watching reality shows.
Others are skeptical about the usefulness of apps for couples. Carole Lieberman, a psychiatrist in Beverly Hills, says “apps are no substitute for real psychotherapy for relationship problems,” and adds that “there’s no quality control over the so-called love coaches who provide them.” And Joy Davidson, a psychotherapist and author, says, “I honestly can’t think of a single app that actually improves one’s sex life — except maybe Tinder — only because it might help you get a sex life if you don’t already have one.”
Moreover, most of the problems in relationships happen offline, says Nick Drydakis, a senior lecturer in economics at Anglia Ruskin University in Cambridge. In his own study — published by the Institute for the Study of Labor in Bonn, Germany — he found that sexual activity is negatively affected by issues like work-related stress, diabetes, heart disease, arthritis, cancer, and psychiatric and psychological symptoms, while it’s positively affected by good mood (extroverted personalities) and marital status (being married, despite widely held beliefs to the contrary) and growing up in a non-religious home.
Read also: Does Facebook break up marriages?
But for the technologically savvy, there is some assistance at hand. Here are five apps that could (maybe) improve your love life:
TheIceBreak
This iOS app has the kind of questionnaire you might find on dating apps, but offers daily questions for couples. They focus on a couple’s emotional and sex life: “Do you think it’s more important for a couple to be friends or lovers?” Others are more reminiscent of the questions asked on the TV show “The Newlywed Game” — for example, “What is ‘your song’ with your partner?” Others get to the point: “Can a romantic evening be complete without having sex?” Couples can also share photos and posts on their private virtual walls. It costs $1.99; some reviews complain about technical glitches.
By
Quentin Fottrell
- Published in Blog
Big investors dump GM, but love Ally
NEW YORK (MarketWatch)—Big investors fell out of love with General Motors in the second quarter but hedge-fund titans including Dan Loeb rushed to snap up shares of Ally Financial, the troubled auto maker’s former financing arm that was rescued by the U.S. government, according to an analysis of freshly-filed regulatory documents.
Hedge funds and other heavyweights were also eager to take up new stakes in pharmaceutical firm Allergan Inc. AGN, -1.01{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Google GOOGL, +0.93{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} The Williams Companies WMB, -0.14{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and DirecTV DTV, +0.04{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} while eliminating stakes in eBay EBAY, +0.68{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} SLM Corp. SLM, +0.23{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Vodafone VOD, +0.88{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and Dollar General DG, +9.05{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} according to Whalewisdom.com, a website that tracks 13F and other regulatory filings.
Institutional investment managers with more than $100 million in certain types of assets have until 45 days after the end of a quarter to file a 13F form listing securities holdings with the Securities and Exchange Commission. The second-quarter filing deadline was Thursday. Whalewisdom provided a breakdown of the biggest aggregate purchases and sales by the 600 most closely-followed investors on its site.
Among Ally’s ALLY, +0.83{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} most ardent supporters, Loeb’s Third Point hedge fund acquired 45.6 million shares in the second quarter. The position made Ally Loeb’s second-largest holding as of June 30, according to the filing, equal to 13.4{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of his overall portfolio and worth $1.09 billion at the end of the quarter.
Fellow hedge-fund titan John Paulson was also in the Ally camp, albeit on a smaller scale, holding a little over 2 million shares, worth nearly $48 million as of June 30. Stephen Feinberg, head of Cerberus Capital Management, took a Loeb-sized stake in the firm, snapping up more than 41.5 million shares worth nearly $993 million as of the end of the quarter.
Ally Financial was rescued by the U.S. government during the financial crisis. It made its debut in an initial public offering on April 10, a transaction that saw the Treasury Department raise nearly $2.4 billion by selling shares at $25 each. Ally soon dipped below its offering price and changed hands at $24.13 in recent action Friday, a 0.4{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} daily decline. Shares are down 0.2{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} since the beginning of the current quarter.
Now, 13F filings don’t offer a full picture of an investors’ positions. Also, the holdings are at least 45 days old. But they can offer insights into the thinking of big investors. Read more about 13Fs.
Big investors appeared to trade heavily during the second quarter in shares of Allergan, the pharmaceutical firm fighting a takeover effort by rival Valeant Pharmaceuticals. That takeover quest has been pushed by activist investor Bill Ackman, whose Pershing Square hedge fund added nearly 28.3 million shares to its stake in Allergan during the quarter. Allergan was Ackman’s top holding with a value of nearly $4.9 billion.
Other activists, including Paulson (who acquired a new stake of 5.6 million shares) also bought into Allergan. Shares of Allergan are up 41.3{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} since the beginning of the year, but have dropped 7.3{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} since June 30.
Also worth noting, hedge-fund legend George Soros significantly loaded up on puts on the SPDR S&P 500 ETF SPY, +0.59{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} while also adding to a smaller holding of calls on the same product. The move raised eyebrows among analysts, who pondered whether it belied a growing sense of caution for the otherwise apparently bullish Soros. See: Does George Soros know something we don’t about the S&P 500?
Meanwhile, positions in eBay were eliminated entirely by around 5.7{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of filers, topping the list of sold-out positions, with big investors dumping a total of nearly 14.7 million shares. Billionaire investor Carl Icahn in April backed away from his contentious demand that eBay spin off its PayPal unit.
Icahn, however, was a buyer of eBay in the second quarter, his 13F filing showed, picking up 3 million shares. EBay shares have rebounded 5.3{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} since the beginning of the third quarter, trimming its year-to-date loss to 4{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}.
General Motors GM, +1.15{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} was dumped entirely by 5{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of big filers as it worked through numerous recalls and scrutiny over vehicle safety. See: Booming demand seen in 10.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} surge in vehicle output.
- Published in Blog
Argex Titanium Engages Liolios Group to Lead New Strategic Investor Relations Program in the United States
MONTREAL, Aug. 18, 2014 /CNW Telbec/ – Argex Titanium, Inc. (TSX: RGX), (“Argex” or the “Company”), an emerging producer of high-grade titanium dioxide (TiO2) used as white pigment in paint, plastic, paper, cosmetics and other applications, has engaged Liolios Group to lead a new strategic investor relations and financial communications program.
“Since I joined Argex a little less than a year ago, we have successfully transitioned the company from the R&D stage to having the unique, patent-protected ability to safely and economically produce highly-valuable titanium dioxide,” said Glen Kayll, CFO of Argex. “Our collaboration and long-term supply agreement with PPG Industries (NYSE: PPG) validates our ‘game-changing’ TiO2 extraction process, and we are now focused on the construction of our first industrial-scale titanium dioxide plant.”
“Given this groundbreaking technology and our rapid advance toward initial commercial production, we believe our shareholders would benefit from an experienced team of investor relations professionals to help us navigate the global capital markets and increase awareness of our story in the financial community,” continued Kayll. “Liolios Group brings to Argex a proven track record of helping Canadian-listed companies like ours enter the U.S. capital markets to enhance shareholder value by delivering the right message to the right audience, and building high-quality, long-term relationships in the U.S. investment community.”
Liolios Group will work closely with Argex management to develop and deploy a comprehensive capital markets strategy and campaign. The campaign will include effective messaging and corporate positioning, strategic advisory, and introductions to investors and key influencers in the financial community. It will also include scheduling road shows and financial conferences for management over the next several months.
For additional information about Argex, contact Liolios Group at 949-574-3860 or email RGX@liolios.com.
About the Innovation
The innovation in Argex’s TiO2 process lies in how the equipment is used, combining well-known technology islands with solvents and chemistry to make TiO2 pigments and high value by-products. Argex’s environmental footprint is reduced as a result of saleable by-products and minimal inert tailings, thereby minimizing costs associated with waste treatment and disposal. Further innovation lies in the ability to run the process at low temperatures and atmospheric pressure.
About Liolios Group
Liolios Group, Inc. is a highly selective and comprehensive investor relations firm specializing in small-cap companies. The firm aims to deliver superior performance in corporate messaging and positioning, investor awareness, analyst and financial press coverage, and capital attraction. Founded in 1999, Liolios Group executives have extensive experience in finance and investments, and represent clients in a wide range of industries, including technology, digital media, consumer/internet retail, healthcare/life sciences, natural resources and business services. For more information about Liolios Group, please visit www.liolios.com.
About Argex Titanium
Argex Titanium Inc. has developed an advanced chemical process for the volume production of high grade titanium dioxide (TiO2) for use in high quality paint, plastics, cosmetics and other applications. The Company’s unique proprietary process takes relatively inexpensive and plentiful source material from a variety of potential vendors, and produces TiO2 along with other valuable by-products. Argex’s process provides a significant cost and environmental advantage over current legacy TiO2 production methods. Argex’s primary near term goal is to rapidly advance toward a 50,000 tonne per annum production module as a first step in its goal to transform the 5.2 million tonne per annum TiO2 industry.
Forward-Looking Statements
This news release contains statements that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information and statements may include, among others, statements regarding future plans, costs, objectives or performance of Argex, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits Argex will derive. Forward-looking statements and information are based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Argex’s control. These risks, uncertainties and assumptions include, but are not limited to, those described under “Risk Factors” in Argex’s Annual Information Form for the fiscal year ended December 31, 2013, which is available on SEDAR at www.sedar.com; they could cause actual events or results to differ materially from those projected in any forward-looking statements. Argex does not intend, nor does Argex undertake any obligation, to update or revise any forward-looking information or statements contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Argex Titanium Inc.
For further information: Company: Argex Titanium, Inc., Roy Bonnell, President and Chief Executive Officer, 514 843-5959; or Sophy Cesar, Manager, Investor Relations, Corporate Communications, Argex Titanium Inc., 514-843-5959 Ext. 128, sophy.cesar@argex.ca; U.S. Investor Relations: Liolios Group Inc., Chris Tyson, Tel 949-574-3860, RGX@liolios.com
- Published in Mining
CANNABIS TECHNOLOGIES ANNOUNCES SECOND THERAPY — CTI-091
CANNABIS TECHNOLOGIES ANNOUNCES SECOND THERAPY — CTI-091
Cannabis Technologies Inc. has developed a therapy containing a proprietary mixture of cannabinoids and non-cannabis-based active ingredients, CTI-091, for the relief of joint pain and swelling associated with arthritis and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation, indicating strong scientific evidence that cannabis extracts reverse the disease progression.
CTI-091 is designed to enhance retention and absorption of the key ingredients around the target site and designed for the relief of joint pain and swelling.
Currently the formulation is in preclinical stage of development. The company is also working to improve the delivery system to increase efficacy. It is expecting to go to initiate clinical phase 1 trials upon completion of these steps.
Craig Schneider, Cannabis Technologies president and chief executive officer, said: “We are extremely pleased to announce a second therapy in our expanding product pipeline. The pain and arthritis therapy takes our company to the next stage of development, reinforcing the proof of concept of our cannabinoid drug design platform. This platform is designed to effectively identify and fast-track new drug therapies. The company plans to have numerous therapies over the next 12 months within the product pipeline focusing on other areas like metabolic diseases (obesity and diabetes), orphan diseases (Huntington’s and epilepsy) as well as cancer and angiogenesis.”
Pain and arthritis market
More than 46 million Americans have arthritis or a related disease, and some experts estimate the global market for arthritis drugs brings as much as $35-billion a year in profits. The many different types of drugs used to treat arthritis and its accompanying pain include over-the-counter and prescription-only drugs, with delivery methods of injections, infusions, patches and topical agents.
We seek Safe Harbor.
- Published in Blog